Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | September 11, 2026 | September 15, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 16, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 525,636 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 14,343 · Balance 525,636 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 517,797 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 7,839 · Balance 517,797 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
Xencor Inc
Report date June 16, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,680 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 21,680 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15 | Direct | 20,604 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 22,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,415 Underlying: Common Stock · 22,415 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 112,644 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,644 Underlying: Common Stock · 112,644 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,832 | $133.02 | $376,700.46 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,596 F1 · kind: Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:02 UTC | Xencor Inc XNCR · Entity 4487 | PurchaseCommon Stock | 53 | $19.12 | $1,013.36 |
DisclosureSEC source: 0001127602-24-005195 · form4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,060 F1 · shares: Shares purchased by the reporting person's investment advisor in a managed account, without the knowledge of the reporting person. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,274 | $134.15 | $305,052.32 |
DisclosureSEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 506,962 F3 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.75 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,040 | $142.18 | $432,218.38 |
DisclosureSEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 504,919 F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,771 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,731) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,707 | $140.69 | $380,844.58 |
DisclosureSEC source: 0000914475-24-000028 · wk-form4_1706919702.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 502,188 F1 · kind: Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 62,023 | $19.59 Strike: $19.59 | $1,215,030.57 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,023 shares Expires 2024-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 62,023 | $134.01 | $8,311,894.50 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,754 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 62,023 | $19.59 | $1,215,030.57 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 561,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 105,835 | $19.59 Strike: $19.59 | $2,073,307.65 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,023 Underlying: Common Stock · 105,835 shares Expires 2024-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 105,835 | $132.44 | $14,016,522.81 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,754 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 105,835 | $19.59 | $2,073,307.65 |
DisclosureSEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2023 Filed Aug 24, 2023 00:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 9,328 | $107.40 | $1,001,816.01 |
DisclosureSEC source: 0001209191-23-047137 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,754 F1 · kind: Sale of 9,328 shares of common stock issued upon vesting of 17,717 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (8,389) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:55 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 10,013 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001127602-23-019287 · form4.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,013 Underlying: Common Stock · 10,013 shares Expires 2033-06-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:55 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 5,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019287 · form4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,007 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 21,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009886 · doc4.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,506 Underlying: Common Stock · 21,506 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 133,656 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001209191-23-009886 · doc4.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,656 Underlying: Common Stock · 133,656 shares Expires 2033-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,274 | $104.30 | $237,184.57 |
DisclosureSEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,365 F8 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.72 to $105.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,482 | $102.43 | $2,098,049.09 |
DisclosureSEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,322 F5 · kind: Sale of 20,482 shares of common stock issued upon vesting of 38,874 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (18,392) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,248 | $102.30 | $332,265.53 |
DisclosureSEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,930 F3 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,170 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,922) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.39 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,040 | $105.68 | $321,258.69 |
DisclosureSEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,008 F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.64 to $108.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,707 | $110.08 | $297,997.12 |
DisclosureSEC source: 0001209191-23-006276 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,278 F1 · kind: Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $111.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:50 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 21,412 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001127602-22-018171 · form4.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,412 Underlying: Common Stock · 21,412 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,274 | $79.49 | $180,767.54 |
DisclosureSEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,844 F7 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $78.98 to $79.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,040 | $80.80 | $245,630.18 |
DisclosureSEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,801 F5 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.73 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,248 | $80.82 | $262,517.98 |
DisclosureSEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,071 F3 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.69 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,422 | $80.83 | $195,758.63 |
DisclosureSEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,150 F1 · kind: Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 00:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 20,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,565 Underlying: Common Stock · 20,565 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 00:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 140,049 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,049 Underlying: Common Stock · 140,049 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| June 24, 2021 Filed Jun 26, 2021 00:01 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 9,728 | $0.00 Strike: $36.01 | $0.00 |
DisclosureSEC source: 0001415889-21-003232 · form4-06252021_080622.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,728 Underlying: Common Stock · 9,728 shares Expires 2031-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 17,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,269 Underlying: Common Stock · 17,269 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 103,609 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,609 Underlying: Common Stock · 103,609 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,248 | $116.71 | $379,089.35 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,972 F7 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 4,343 | $116.74 | $506,999.21 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,051 F5 · kind: Sale of 4,343 shares of common stock issued upon vesting of 8,250 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (3,907) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.89 to $117.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,875 | $116.79 | $335,774.99 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,144 F3 · kind: Sale of 2,875 shares of common stock issued upon vesting of 5,770 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,895) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:19 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 113,863 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023379 · doc4a.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,863 Underlying: Common Stock · 113,863 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,422 | $114.16 | $276,504.48 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,249 F1 · kind: Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.51 to $116.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 164,801 | $8.65 Strike: $8.65 | $1,425,528.65 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,801 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 143,449 | $8.66 Strike: $8.66 | $1,242,268.34 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 143,449 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 164,801 | $110.22 | $18,164,778.22 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,071 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 164,801 | $8.65 | $1,425,528.65 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 143,449 | $110.21 | $15,809,098.29 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,071 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 143,449 | $8.66 | $1,242,268.34 |
DisclosureSEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,390 | $90.78 | $307,747.59 |
DisclosureSEC source: 0001209191-20-058545 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,071 F1 · kind: Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding taxes, with the balance of the shares (3,050) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $89.05 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,390 | $118.91 | $403,101.17 |
DisclosureSEC source: 0001209191-20-045753 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,021 F1 · kind: Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding taxes, with the balance of the shares (3,050) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.16 to $120.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 00:24 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 13,953 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001209191-20-039288 · doc4.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 13,953 shares Expires 2030-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,906 | $99.45 | $289,015.65 |
DisclosureSEC source: 0001209191-20-026068 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,971 F1 · kind: Sale of 2,906 shares of common stock issued upon vesting of 5,520 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (2,614) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,248 | $103.35 | $335,696.07 |
DisclosureSEC source: 0001209191-20-008494 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,357 F1 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.985 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 23,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,081 Underlying: Common Stock · 23,081 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.